-$0.76 EPS Expected for Voyager Therapeutics Inc (VYGR) This Quarter

Equities research analysts expect Voyager Therapeutics Inc (NASDAQ:VYGR) to report ($0.76) earnings per share for the current quarter, according to Zacks. Four analysts have made estimates for Voyager Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.46) and the lowest estimate coming in at ($0.91). Voyager Therapeutics reported earnings per share of ($0.89) during the same quarter last year, which suggests a positive year over year growth rate of 14.6%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Voyager Therapeutics will report full year earnings of ($3.12) per share for the current financial year, with EPS estimates ranging from ($3.41) to ($2.43). For the next year, analysts expect that the company will post earnings of ($3.39) per share, with EPS estimates ranging from ($4.29) to ($2.60). Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings results on Tuesday, August 7th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.13). The company had revenue of $2.58 million for the quarter, compared to analyst estimates of $3.00 million. Voyager Therapeutics had a negative return on equity of 80.68% and a negative net margin of 731.88%.

VYGR has been the subject of several research reports. BidaskClub cut shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 20th. ValuEngine cut shares of Voyager Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, September 17th. HC Wainwright set a $30.00 price target on shares of Voyager Therapeutics and gave the stock a “buy” rating in a report on Wednesday, August 8th. Canaccord Genuity reiterated a “buy” rating and issued a $31.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, July 17th. Finally, Morgan Stanley cut shares of Voyager Therapeutics from an “overweight” rating to an “equal” rating in a research note on Monday, September 10th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $31.09.

In other Voyager Therapeutics news, Director Glenn Pierce purchased 5,000 shares of the stock in a transaction on Wednesday, September 12th. The shares were purchased at an average price of $18.44 per share, with a total value of $92,200.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director James A. Geraghty purchased 3,000 shares of the stock in a transaction on Friday, August 17th. The stock was acquired at an average cost of $18.31 per share, for a total transaction of $54,930.00. Following the acquisition, the director now directly owns 73,588 shares in the company, valued at $1,347,396.28. The disclosure for this purchase can be found here. Insiders acquired a total of 11,000 shares of company stock worth $205,300 in the last three months. Insiders own 33.60% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC boosted its stake in shares of Voyager Therapeutics by 38.6% in the 2nd quarter. MetLife Investment Advisors LLC now owns 10,649 shares of the company’s stock valued at $208,000 after purchasing an additional 2,964 shares in the last quarter. Rhumbline Advisers boosted its stake in shares of Voyager Therapeutics by 18.3% in the 2nd quarter. Rhumbline Advisers now owns 20,258 shares of the company’s stock valued at $396,000 after purchasing an additional 3,132 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Voyager Therapeutics by 53.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 9,048 shares of the company’s stock valued at $177,000 after purchasing an additional 3,157 shares in the last quarter. Commonwealth Equity Services LLC boosted its stake in shares of Voyager Therapeutics by 27.4% in the 2nd quarter. Commonwealth Equity Services LLC now owns 16,272 shares of the company’s stock valued at $318,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Barclays PLC boosted its stake in shares of Voyager Therapeutics by 19.9% in the 1st quarter. Barclays PLC now owns 32,577 shares of the company’s stock valued at $612,000 after purchasing an additional 5,415 shares in the last quarter. 89.64% of the stock is currently owned by hedge funds and other institutional investors.

VYGR stock opened at $16.95 on Friday. The company has a market cap of $613.69 million, a P/E ratio of -6.42 and a beta of 2.94. Voyager Therapeutics has a 52 week low of $11.54 and a 52 week high of $31.91.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.

Featured Article: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply